Literature DB >> 30523111

A mechanistic classification of clinical phenotypes in neuroblastoma.

Sandra Ackermann1,2, Maria Cartolano2,3, Barbara Hero4, Anne Welte1,2, Yvonne Kahlert1,2, Andrea Roderwieser1,2, Christoph Bartenhagen1,2, Esther Walter1,2, Judith Gecht4, Laura Kerschke5, Ruth Volland4, Roopika Menon6, Johannes M Heuckmann6, Moritz Gartlgruber7, Sabine Hartlieb7, Kai-Oliver Henrich7, Konstantin Okonechnikov8, Janine Altmüller2,9, Peter Nürnberg2,9,10, Steve Lefever11, Bram de Wilde11, Frederik Sand1,2, Fakhera Ikram1,2,12, Carolina Rosswog1,2, Janina Fischer1,2, Jessica Theissen1,4, Falk Hertwig1,2,13,14,15, Aatur D Singhi16, Thorsten Simon4, Wenzel Vogel17,18, Sven Perner17,18, Barbara Krug19, Matthias Schmidt20, Sven Rahmann21,22, Viktor Achter23, Ulrich Lang23,24, Christian Vokuhl25, Monika Ortmann26, Reinhard Büttner26, Angelika Eggert13,14,15, Frank Speleman11, Roderick J O'Sullivan27, Roman K Thomas3,14,26,28, Frank Berthold4, Jo Vandesompele11, Alexander Schramm29, Frank Westermann7, Johannes H Schulte13,14,15,28, Martin Peifer2,3, Matthias Fischer30,2.   

Abstract

Neuroblastoma is a pediatric tumor of the sympathetic nervous system. Its clinical course ranges from spontaneous tumor regression to fatal progression. To investigate the molecular features of the divergent tumor subtypes, we performed genome sequencing on 416 pretreatment neuroblastomas and assessed telomere maintenance mechanisms in 208 of these tumors. We found that patients whose tumors lacked telomere maintenance mechanisms had an excellent prognosis, whereas the prognosis of patients whose tumors harbored telomere maintenance mechanisms was substantially worse. Survival rates were lowest for neuroblastoma patients whose tumors harbored telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. Spontaneous tumor regression occurred both in the presence and absence of these mutations in patients with telomere maintenance-negative tumors. On the basis of these data, we propose a mechanistic classification of neuroblastoma that may benefit the clinical management of patients.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30523111     DOI: 10.1126/science.aat6768

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  83 in total

1.  Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

Authors:  Elizabeth Sokol; Ami V Desai; Mark A Applebaum; Dominique Valteau-Couanet; Julie R Park; Andrew D J Pearson; Gudrun Schleiermacher; Meredith S Irwin; Michael Hogarty; Arlene Naranjo; Samuel Volchenboum; Susan L Cohn; Wendy B London
Journal:  J Clin Oncol       Date:  2020-04-21       Impact factor: 44.544

2.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

3.  Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.

Authors:  Wayne H Liang; Sara M Federico; Wendy B London; Arlene Naranjo; Meredith S Irwin; Samuel L Volchenboum; Susan L Cohn
Journal:  JCO Clin Cancer Inform       Date:  2020-10

Review 4.  Genome rearrangements associated with aberrant telomere maintenance.

Authors:  Ragini Bhargava; Matthias Fischer; Roderick J O'Sullivan
Journal:  Curr Opin Genet Dev       Date:  2020-03-04       Impact factor: 5.578

5.  Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression.

Authors:  Min Huang; Jasmine Zeki; Nathan Sumarsono; Garry L Coles; Jordan S Taylor; Enrico Danzer; Matias Bruzoni; Florette K Hazard; Norman J Lacayo; Kathleen M Sakamoto; James C Y Dunn; Sheri L Spunt; Bill Chiu
Journal:  Cancer Res       Date:  2020-01-03       Impact factor: 12.701

6.  Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma.

Authors:  Selina Jansky; Ashwini Kumar Sharma; Verena Körber; Andrés Quintero; Umut H Toprak; Elisa M Wecht; Moritz Gartlgruber; Alessandro Greco; Elad Chomsky; Thomas G P Grünewald; Kai-Oliver Henrich; Amos Tanay; Carl Herrmann; Thomas Höfer; Frank Westermann
Journal:  Nat Genet       Date:  2021-03-25       Impact factor: 38.330

7.  An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.

Authors:  Ruth Flümann; Tim Rehkämper; Pascal Nieper; Hans Christian Reinhardt; Gero Knittel; Pauline Pfeiffer; Alessandra Holzem; Sebastian Klein; Sanil Bhatia; Moritz Kochanek; Ilmars Kisis; Benedikt W Pelzer; Heinz Ahlert; Julia Hauer; Alexandra da Palma Guerreiro; Jeremy A Ryan; Maurice Reimann; Arina Riabinska; Janica Wiederstein; Marcus Krüger; Martina Deckert; Janine Altmüller; Andreas R Klatt; Lukas P Frenzel; Laura Pasqualucci; Wendy Béguelin; Ari M Melnick; Sandrine Sander; Manuel Montesinos-Rongen; Anna Brunn; Philipp Lohneis; Reinhard Büttner; Hamid Kashkar; Arndt Borkhardt; Anthony Letai; Thorsten Persigehl; Martin Peifer; Clemens A Schmitt
Journal:  Blood Cancer Discov       Date:  2021-01

8.  Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma.

Authors:  Daheng Yang; Xianwei Zhang; Zheqian Li; Fei Xu; Chenjie Tang; Hongbing Chen
Journal:  PeerJ       Date:  2021-06-01       Impact factor: 2.984

Review 9.  Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy?

Authors:  Kiyohiro Ando; Akira Nakagawara
Journal:  Biomolecules       Date:  2021-05-18

Review 10.  A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.

Authors:  Vid Mlakar; Edouard Morel; Simona Jurkovic Mlakar; Marc Ansari; Fabienne Gumy-Pause
Journal:  J Exp Clin Cancer Res       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.